Access to anti-retroviral drugs, female in France

France: Access to anti-retroviral drugs, female was 93.0% in 2022. ▲ Rising

Latest (2022)
93.0%
Change on year
up 1.1%
World rank
22nd
of 141 countries
All-time high
93.0%
in 2022
All-time low
69.0%
in 2000
Years of data
23
2000–2022

Access to anti-retroviral drugs, female in France, 2000–2022

0204060801002000201120222000: 69 %2001: 72 %2002: 75 %2003: 79 %2004: 82 %2005: 85 %2006: 86 %2007: 87 %2008: 88 %2009: 89 %2010: 89 %2011: 90 %2012: 90 %2013: 91 %2014: 91 %2015: 92 %2016: 91 %2017: 91 %2018: 89 %2019: 90 %2020: 90 %2021: 92 %2022: 93 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2022, access to anti-retroviral drugs, female in France stood at 93.0%. That is the highest value across all 23 years on record.

The figure is up 1.1% on the previous year and up 3.3% over ten years.

Over the whole period, access to anti-retroviral drugs, female in France peaked at 93.0% in 2022 and was at its lowest, 69.0%, in 2000.

That places France 22nd out of 141 countries with data for 2022, putting it in the top quarter.

The long-run direction has been consistently rising across the 23 years of available data.

Access to anti-retroviral drugs, female in France, year by year

Annual values for Access to anti-retroviral drugs, female (%) in France, 2000 to 2022.
Year % Change
2000 69.0%
2001 72.0% +4.3%
2002 75.0% +4.2%
2003 79.0% +5.3%
2004 82.0% +3.8%
2005 85.0% +3.7%
2006 86.0% +1.2%
2007 87.0% +1.2%
2008 88.0% +1.1%
2009 89.0% +1.1%
2010 89.0% +0.0%
2011 90.0% +1.1%
2012 90.0% +0.0%
2013 91.0% +1.1%
2014 91.0% +0.0%
2015 92.0% +1.1%
2016 91.0% -1.1%
2017 91.0% +0.0%
2018 89.0% -2.2%
2019 90.0% +1.1%
2020 90.0% +0.0%
2021 92.0% +2.2%
2022 93.0% +1.1%

Averages by decade

DecadeAverage LowestHighest Years
2000s 81.2% 69.0% 89.0% 10
2010s 90.4% 89.0% 92.0% 10
2020s 91.7% 90.0% 93.0% 3

Countries ranked near France

  1. 19 Cameroon 95.0% compare
  2. 19 Sierra Leone 95.0% compare
  3. 19 Tajikistan 95.0% compare
  4. 22 Malawi 93.0% compare
  5. 22 Morocco 93.0% compare
  6. 25 Denmark 91.0% compare
  7. 25 Saudi Arabia 91.0% compare

See the full ranking of 160 places →

More gender data for France

All data for France →

Frequently asked questions

What is access to anti-retroviral drugs, female in France?
Access to anti-retroviral drugs, female in France was 93.0% in 2022, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in France?
The highest recorded value was 93.0% in 2022.
What is the lowest access to anti-retroviral drugs, female recorded in France?
The lowest recorded value was 69.0% in 2000.
How does France rank for access to anti-retroviral drugs, female?
France ranks 22nd out of 141 countries with data for 2022.
Is access to anti-retroviral drugs, female rising or falling in France?
Over the last ten years it is up 3.3%. The long-run trend across the full record is rising.
Where does this France data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 23 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in France. Statizoid, drawing on UNAIDS estimates. Retrieved 09 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/france/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/france/">Access to anti-retroviral drugs, female in France</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.